Trial from ANZCTR


Trial ID ACTRN12611001008910
Trial Status: Registered
Date Submitted: 17/09/2011
Date Registered: 20/09/2011
Prospectively registered

Page 1

Public title A Phase II clinical trial to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.
Update:
 
Reason:
 
Study title in 'Participant- Intervention- Comparator- Outcome (PICO)' format A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.
Update:
 
Reason:
 
Secondary ID [1] 262995 0
Nil
Update:
 
Reason:
 
UTN U1111-1124-2486
Update:
 
Reason:
 
Trial acronym PBT2-204 / IMAGINE
Update:
 

Page 2

Health condition(s) or problem(s) studied:
Prodromal Alzheimer's disease or mild Alzheimer's disease 270699 0
 Update:
 Reason:
Condition category: Condition code:
Mental Health Other mental health disorders
 Update:
 Update:
  Reason:
270873 270873 0 0
Neurological Dementias
 Update:
 Update:
  Reason:
271010 271010 0 0

Page 3

Descriptions of intervention(s) / exposure PBT2 is supplied as 250mg immediate-release capsules. The dose for this study is 250mg / day ie. one capsule is to be taken orally, once a day for 52 weeks duration.
Update:
 
Reason:
 
Intervention Code:
Treatment: drugs 269318 0
Update:
 
Reason:
 
Comparator / control treatment Placebo is supplied as identical looking, immediate-release capsules. One capsule is to be taken orally, once a day for 52 weeks duration.
Update:
 
Reason:
 
Control group Placebo
Update:
 
Reason:
 

Page 4

Primary Outcome: To evaluate the effect of PBT2 compared to placebo on brain amyloid levels after 52 weeks of treatment as measured by Carbon 11-Pittsburgh Imaging Compound-B (PiB) Positron Emission Tomography (PET) imaging. 279555 0
Update:
 
Reason:
 
Timepoint: Baseline, 26 and 52 weeks after commencement of treatment with PBT2/placebo 279555 0
Update:
 
Reason:
 
Secondary Outcome: To evaluate the safety and tolerability of PBT2 compared to placebo as measured by capture of vital signs, physical examination, neurological examination, ECG, eye examination, blood haematology and biochemistry, urinalysis and recording of adverse events.
From previous clinical trials, the most commonly reported side effects that were possibly related to PBT2 were fatigue (tiredness), headache, dizziness, nasopharyngitis (swollen blocked nose), and somnolence (drowsiness). Less common side-effects possibly related to PBT2 were diarrhoea, back pain, nausea and pharyngolaryngeal (throat) pain. It is possible that a rare side effect may be dissociation (a feeling of disconnecting from one's thoughts, feelings, memories or self).
287893 0
Update:
 
Reason:
 
Timepoint: Baseline, 4, 8, 13, 19, 26, 33, 39, 45 and 52 weeks after commencement of treatment with PBT2/placebo and 4 weeks after cessation of treatment with PBT2/placebo 287893 0
Update:
 
Reason:
 
Secondary Outcome: To evaluate the effect of PBT2 compared to placebo on brain metabolic activity after 52 weeks as measured by Fluorine 18 labelled Fluorodeoxyglucose (FDG) PET imaging. 287894 0
Update:
 
Reason:
 
Timepoint: Baseline and 52 weeks after commencement of of treatment withPBT2/placebo 287894 0
Update:
 
Reason:
 
Secondary Outcome: To evaluate the effect of PBT2 compared to placebo on brain volumes after 52 weeks as assessed by Magnetic Resonance Imaging (MRI) to measure the cortical grey matter volume, hippocampal volume and ventricular volume. 287895 0
Update:
 
Reason:
 
Timepoint: Baseline and 52 weeks after commencement of of treatment withPBT2/placebo 287895 0
Update:
 
Reason:
 
Secondary Outcome: To evaluate the effect of PBT2 compared to placebo on cognition after 52 weeks as measured by a Neuropsychological Test Battery (NTB) questionnaires and the Mini-mental State Examination (MMSE) questionnaire. 287896 0
Update:
 
Reason:
 
Timepoint: Baseline, 13, 26, 39 and 52 weeks after commencement of treatment with PBT2/placebo 287896 0
Update:
 
Reason:
 
Secondary Outcome: To evaluate the effect of PBT2 compared to placebo on functional ability after 52 weeks as measured by the Alzheimer's disease Cooperative Study-Activities of Daily Living-23 (ADCS-ADL-23) questionnaire 287897 0
Update:
 
Reason:
 
Timepoint: Baseline and 52 weeks after commencement of treatment with PBT2/placebo 287897 0
Update:
 
Reason:
 

Page 5

Key inclusion criteria 1. Prodromal Alzheimer's disease or mild Alzheimer's disease
2. 11C-PiB-PET positive (SUVR>1.7)
3. MMSE >or= 20
Update:
 
Reason:
 
Minimum age 55 Years
Update:
 
Reason:
 
Update:
 
Reason:
 
Maximum age No limit
Update:
 
Reason:
 
Update:
 
Reason:
 
Gender Both males and females
Update:
 
Reason:
 
Healthy volunteers? No
Update:
 
Reason:
 
Key exclusion criteria 1. Allergy to PBT2 or its excipients (microcrystalline cellulose, pregelatinised starch, colloidal silicon dioxide, povidone K29/32 and sodium stearyl fumurate).
2. Have other primary neurodegenerative disorders associated with dementia (e.g. Parkinson’s Disease Dementia, Fronto-temporal Lobe Dementia, Lewy Body Dementia or Vascular Dementia)
Update:
 
Reason:
 

Page 6

Study type Interventional
Update:
 
Reason:
 
Purpose of the study Treatment
Update:
 
Allocation to intervention Randomised controlled trial
Update:
 
Reason:
 
Describe the procedure for enrolling a subject and allocating the treatment (allocation concealment procedures) Eligible participants will be entered on to the trial in sequence as their eligibility is confirmed. Participants will be allocated a unique Randomisation ID Number. Each participant will receive only PBT2 or placebo, with treatment assigned according to a Randomisation Schedule prepared by an independent statistician.
Update:
 
Reason:
 
Describe the methods used to generate the sequence in which subjects will be randomised (sequence generation) The Randomisation Schedule is generated by an independent statistician at a ratio of 2:1 ie. 2/3 participants will receive 250mg PBT2 and 1/3 participants will receive matching placebo.
Update:
 
Reason:
 
Masking / blinding Blinded (masking used)
Update:
 
Reason:
 
Who is / are masked / blinded (choose all that apply) The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Update:
       
Reason:
 
Assignment Parallel
Update:
 
Reason:
 
Other design features
Update:
 
Reason:
 
Type of endpoint(s) Safety/efficacy
Update:
 
Reason:
 
Statistical Methods/Analysis
Update:
 
Reason:
 

Page 7

Phase Phase 2
Update:
 
Reason:
 
Anticipated date of first participant enrolment 17/10/2011
Update:
 
Reason:
 
Date of first participant enrolment 2/03/2012
Update:
 
Reason:
 
Anticipated date last participant recruited/enrolled
Update:
 
Reason:
 
Actual date last participant recruited/enrolled 28/11/2012
Update:
 
Reason:
 
Target sample size 42
Update:
 
Reason:
 
Recruitment status Closed: follow-up complete
Update:
 
Reason:
 

Recruitment in Australia

Recruitment state(s)
Update:
 
Reason:
 
Hospital: Austin Health - Heidelberg Repatriation Hospital - Heidelberg West 498 0
Update:
 
Reason:
 
Hospital: Caulfield Hospital - Caulfield 499 0
Update:
 
Reason:
 
Hospital: Delmont Private Hospital - Glen Iris 500 0
Update:
 
Reason:
 
Hospital: Royal Melbourne Hospital - City campus - Parkville 501 0
Update:
 
Reason:
 
Hospital: Barwon Health - Geelong Hospital campus - Geelong 502 0
Update:
 
Reason:
 
Postcode: 3081 4456 0
Update:
 
Reason:
 
Postcode: 3162 4457 0
Update:
 
Reason:
 
Postcode: 3146 5419 0
Update:
 
Reason:
 
Postcode: 3050 - Royal Melbourne Hospital 6242 0
Update:
 
Reason:
 
Postcode: 3220 - Geelong 6243 0
Update:
 
Reason:
 

Recruitment outside Australia

Page 8

Funding Source: Charities/Societies/Foundations 269806 0
Update:
 
Reason:
 
Name: Alzheimer's Drug Discovery Foundation (ADDF) 269806 0
Update:
 
Reason:
 
Address: 57 West 57th Street,
Suite 904,
NEW YORK,
NY 10019 New York
269806 0
Update:
 
Reason:
 
Country: United States of America 269806 0
Update:
 
Reason:
 
Primary Sponsor Commercial sector/Industry
Update:
 
Reason:
 
Name: Prana Biotechnology Limited
Update:
 
Reason:
 
Address: Level 2, 369 Royal Parade
Parkville 3052
Victoria
Update:
 
Reason:
 
Country: Australia
Update:
 
Reason:
 
Secondary Sponsor: None 268841 0
Update:
 
Reason:
 
Name: 268841 0
Update:
 
Reason:
 
Address: 268841 0
Update:
 
Reason:
 
Country: 268841 0
Update:
 
Reason:
 

Page 9

Has the study received approval from at least one Ethics Committee? Yes
Update:
 
Reason:
 
Ethics Committee name: Austin Health Human Research Ethics Committee 271769 0
Update:
 
Reason:
 
Address: Henry Buck Building
Austin Hospital
145 Studley Road
Heidelberg 3084
Victoria
271769 0
Update:
 
Reason:
 
Country: Australia 271769 0
Update:
 
Reason:
 
Approval Date: 17/11/2011 271769 0
Update:
 
Reason:
 
Submitted Date: 17/08/2011 271769 0
Update:
 
Reason:
 
HREC: HREC/11/Austin/42 271769 0
Update:
 
Reason:
 
Brief summary This is a Phase II clinical trial to examine the safety, tolerability and effect of 52 weeks treatment with PBT2 in patients with prodromal or mild Alzheimer's disease (AD). The primary objective is to compare the effect of PBT2 vs placebo on the amount of amyloid in patients brains after 52 weeks of treatment when measured by a particular type of brain scan, PiB-Positron Emission Tomography (PET). The effects of PBT2 on safety and tolerability, brain volume, brain metabolic activity, and cognition plus functional abilities will also be investigated.
Update:
 
Reason:
 
Trial website
Update:
 
Trial related presentations / publications 1. Adlard PA, Cherny R, Finkelstein DI et al (2008). Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-Hydroxy Quinoline analogs is associated with decreased interstitial Aß. Neuron 59: 43–55.
2. Adlard PA, Bica L, White AR et al (2011). Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer’s Disease. PLoS ONE 6: e17669. doi:10.1371/journal.pone.0017669.
3. Faux NG, Ritchie CW, Gunn A et al (2010). PBT2 rapidly improves cognition in Alzheimer's disease: additional Phase II analyses. J Alzheimers Dis 20: 509-16.
4. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131: 1630-45.
5. Klunk WE, Engler H, Nordberg A et al (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55: 306-19.
6. Lannfelt L, Blennow K, Zetterberg H et al (2008). Safety, efficacy and biomarker findings of PBT2 in targeting Aß as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779-86. Erratum in: Lancet Neurol (2009) 8: 981.
7. Rowe CC, Ng S, Ackermann U et al (2007). Imaging ß-amyloid burden in aging and dementia. Neurology 68: 1718-25.
Update:
 
Public Notes
Update:
 

Page 10

Principal Investigator
Title: A/Prof
Update:
 
Reason:
 
33105 0
Name: Associate Professor Michael Woodward
Update:
 
Reason:
 
33105 0
Address: Medical & Cognitive Research Unit Heidelberg Repatriation Hospital 300 Waterdale Road Heidelberg West, VIC 3081
Update:
 
Reason:
 
33105 0
Country: Australia
Update:
 
33105 0
Reason:
 
Tel: +61 (0)3 9496 2852
Update:
 
Reason:
 
33105 0
Fax:
Update:
 
Reason:
 
33105 0
Email: michael.woodward@austin.org.au
Update:
 
Reason:
 
33105 0
Contact person for public queries
Title: Ms
Update:
 
Reason:
 
16352 0
Name: Dianne Angus
Update:
 
Reason:
 
16352 0
Address: Prana Biotechnology Limited Level 2, 369 Royal Parade Parkville 3052 Victoria
Update:
 
Reason:
 
16352 0
Country: Australia
Update:
 
16352 0
Reason:
 
Tel: +61 (0)3 9349 4906
Update:
 
Reason:
 
16352 0
Fax: +61 (0)3 9348 0377
Update:
 
Reason:
 
16352 0
Email: info@pranabio.com
Update:
 
Reason:
 
16352 0

Contact person for scientific queries
Title: Ms
Update:
 
Reason:
 
7280 0
Name: Dianne Angus
Update:
 
Reason:
 
7280 0
Address: Prana Biotechnology Limited Level 2, 369 Royal Parade Parkville 3052 Victoria
Update:
 
Reason:
 
7280 0
Country: Australia
Update:
 
7280 0
Reason:
 
Tel: +61 (0)3 9349 4906
Update:
 
Reason:
 
7280 0
Fax: +61 (0)3 9348 0377
Update:
 
Reason:
 
7280 0
Email: info@pranabio.com
Update:
 
Reason:
 
7280 0

Contact person responsible for updating information
Title:
Update:
 
Reason:
 
25424 0
Name:
Update:
 
Reason:
 
25424 0
Address:
Update:
 
Reason:
 
25424 0
Country: Australia
Update:
 
25424 0
Reason:
 
Tel:
Update:
 
Reason:
 
25424 0
Fax:
Update:
 
Reason:
 
25424 0
Email:
Update:
 
Reason:
 
25424 0
   

Addition Cancer fields
Update:
 
Reason:
 
Update:
 
Reason:
 
Update:
 
Reason:
 
Update:
 
Reason:
 
Update:
 
Reason:
 
Update:
 
Reason: